Medarex

What Medarex does

Medarex is a biopharmaceutical company historically focused on monoclonal antibody discovery and development, best known for its UltiMAb technology platform. The company was acquired by Bristol-Myers Squibb (NYSE: BMY) in 2009 and currently operates as a wholly-owned subsidiary, with its antibody technologies and capabilities integrated into BMS's broader discovery and development operations rather than maintained as a discrete commercial business. The specific founding date of Medarex is not disclosed in the available source data.

The strategic rationale of the acquisition was to strengthen BMS's pipeline in immunology and oncology through Medarex's monoclonal antibody expertise. Today, Medarex contributes legacy assets and know-how that support BMS's five core therapeutic areas — Oncology, Hematology, Neuroscience, Immunology, and Cardiovascular — and its research pipeline of 50 compounds across 40+ disease areas as of April 30, 2026. No Medarex-specific products, revenue streams, partnerships, or pricing models are disclosed; all observable commercial activity (global field sales, distribution networks, foundation partnerships, social impact programs) is conducted at the BMS parent level.

Because Medarex no longer operates as an independent revenue-generating entity and its financials are consolidated into Bristol-Myers Squibb, entity-level analysis of revenue, headcount, and growth is not feasible from the available data. Any assessment of Medarex as an investment target should be framed in the context of its role as an integrated antibody technology contributor within BMS's global biopharmaceutical franchise.

Name

Medarex

Legal name

Bristol-Myers Squibb Company

Website

https://medarex.com

Company type

Public

Founded year

1987

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Medarex is a biopharmaceutical company historically focused on monoclonal antibody discovery via its UltiMAb platform, acquired by Bristol Myers Squibb in 2009 and now operating as a wholly-owned subsidiary integrated into BMS's oncology and immunology R&D operations.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• Monoclonal antibody therapeutics
• Biopharmaceutical medicines
• Oncology drug development
• Hematology treatments
• Clinical trial pipeline

Headquarters

HQ city

Princeton

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from the sale of prescription pharmaceutical medicines across multiple therapeutic areas including oncology, hematology, neuroscience, immunology, and cardiovascular diseases. Products are sold globally through direct sales channels to healthcare providers, hospitals, pharmacies, and distributors.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels9 records

Core offering

Medarex was a biopharmaceutical company focused on monoclonal antibody discovery and development through its UltiMAb technology platform. Following its 2009 acquisition by Bristol-Myers Squibb, Medarex's antibody capabilities have been integrated into BMS's broader pharmaceutical portfolio, which spans five core therapeutic areas (oncology, hematology, neuroscience, immunology, cardiovascular) with 50 compounds in development across 40+ disease areas as of April 30, 2026.

Product overview

Bristol Myers Squibb operates as a global biopharmaceutical company with a diversified portfolio spanning five core therapeutic areas: Oncology (solid tumor treatments), Hematology (blood disorders), Neuroscience (neurological and psychiatric diseases), Immunology (dermatology, gastroenterology, pulmonology, rheumatology), and Cardiovascular (heart disease treatments). The company maintains an active research pipeline with 50 compounds in development targeting 40+ disease areas. Note: Medarex was acquired by Bristol-Myers Squibb in 2009 and its legacy technologies have been integrated into BMS's discovery and development operations.

Differentiator

Problem solved

Functional benefit

Products and services

• Oncology Therapeutics Solid tumor oncology franchise building on a heritage in cancer treatment, focused on solving complex scientific problems for cancer patients. Includes medicines, clinical research, and development programs targeting solid tumors and hematologic malignancies.
• Hematology Therapeutics Therapeutic franchise for blood disorders and hematologic diseases, with a track record of delivering transformational firsts in hematology treatments for patients with high unmet need.
• Neuroscience Therapeutics Therapeutic franchise focused on disease-modifying and symptomatic therapies for patients living with neurological and psychiatric diseases.
• Immunology Therapeutics Therapeutic franchise delivering solutions that address unmet needs in dermatology, gastroenterology, pulmonology, and rheumatology for patients with immunological conditions across multiple organ systems.
• Cardiovascular Therapeutics Cardiovascular franchise building on a 70-year legacy of paradigm-changing medicines, leveraging experience and expertise to advance cardiovascular research and treatments.
• Research and Development Pipeline (50 Compounds) Active R&D pipeline with 50 compounds in development across 40+ disease areas as of April 30, 2026, targeting transformative medicines for patients with high unmet need.

Segments6 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Bristol Myers Squibb FoundationcoreStrategic or Co-development PartnerThe Bristol Myers Squibb Foundation is part of the company's corporate giving and social impact initiatives, focusing on advancing population health, patient advocacy, and providing access to life-saving medicines in low- and middle-income countries. Works to bring life-saving medicines to more patients globally.

Scale indicators3 records

Recent moves2 records

Expansion highlights2 records

Broad incumbents

• AbbVie: Immunology heavyweight (Humira/Skyrizi/Rinvoq) with oncology and neuroscience exposure. Comparable branded-innovator pharma model and immunology franchise depth.
• Novartis: Diversified innovator pharma with parallel exposure to oncology, hematology, neuroscience, and cardiovascular. Comparable pipeline scale and therapeutic-area breadth.
• Pfizer: Global biopharmaceutical company with overlapping therapeutic areas in oncology, immunology, hematology, and cardiovascular. Comparable as a diversified innovator pharma competing for similar high-unmet-need indications.
• Johnson & Johnson (Innovative Medicine): Innovative medicine arm with major oncology and immunology franchises. Direct peer across solid tumor, hematology, and immunology indications.
• AstraZeneca: Global pharma with leading oncology franchise and growing immunology and cardiovascular pipelines. Comparable oncology-solid-tumor focus and pipeline-driven diversification.
• Merck & Co. Major oncology-focused innovator pharma (Keytruda) with growing immunology and pipeline breadth. Direct competitor in oncology solid tumors and an analogous pipeline-driven growth model.
• Eli Lilly: Innovator pharma with strong oncology, immunology, and neuroscience pipelines. Comparable breadth and pipeline-driven growth strategy with biologics and novel modalities.
• Roche: Global biopharmaceutical leader with deep oncology and immunology franchises and significant biologics capability. Comparable as a multi-TA innovator with strong biologics and antibody platforms.

Direct peers

• Amgen: Biologics pioneer with deep antibody and protein-therapeutic capability across oncology, hematology, and inflammation. Directly comparable as a biologic-platform innovator in overlapping therapeutic areas.
• Regeneron Pharmaceuticals: Antibody-discovery leader (VelociSuite) with major ophthalmology, oncology, and immunology franchises. Closely comparable to Medarex's antibody-engineering heritage and biologic modality focus.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xtwitter.com/BMSNEWS
• YouTubeyoutube.com/bristolmyerssquibb
• Facebookfacebook.com/BristolMyersSquibb
• LinkedInlinkedin.com/company/medarex
• Instagraminstagram.com/bristolmyerssquibb

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medarex